The first test designed to help diagnose Long COVID is due to launch in the UK and EU, as a result of a collaboration between health tech companies, PeploBio and IncellDX.
Long COVID, a condition characterised by persistent symptoms following a COVID-19 infection, continues to present a significant challenge for both patients and healthcare providers.
It is thought to affect more than 65 million worldwide, with typical symptoms ranging from fatigue, brain fog, shortness of breath, insomnia, to a spectrum of cardiovascular issues.
PeploBio, a clinical laboratory committed to elevating precision medicine and bringing innovative diagnostic solutions to improve patient outcomes, has partnered with IncellDX to utilise its innovative technology platform which enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.
Together they have launched the first laboratory developed test in the UK and EU to designed to help diagnose Long COVID, providing doctors with accurate insights into personalised treatment approaches using the incellKINE Long Hauler Index technology.
Many of the symptoms of Long COVID overlap with those of other chronic conditions and autoimmune diseases, such as Lyme, ME-CFS and fibromyalgia.
The breakthrough aims to provide physicians with a definitive tool to differentiate Long COVID from other diseases.
Bruce Patterson, M.D, founder and CEO at IncellDX, commented: “Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to Long COVID patients, providing a crucial first step for personalised treatment strategies.”
Dr Nico Lambri, managing director at PeploBio, added: “Our mission at PeploBio is to drive innovation in diagnostics, and our partnership with IncellDX underscores our commitment to advancing healthcare solutions. The introduction of this test fills a critical gap, empowering healthcare professionals with the tools needed to address the challenges posed by Long COVID.”
